BibTex RIS Cite

Cardiovascular Side Effects of Anticancer Drugs: How These Side Effects Should be Identified, Treated, and Followed up?

Year 2011, Volume: 18 Issue: 2, 137 - 142, 01.04.2011

Erdal Aktürk Ertuğrul Kurtoğlu Hakan Harputluoğlu

Abstract

The changes in cancer treatment and conditions of early diagnosis and treatment and the use of new anticancer drugs has substantially increased the rate of cure for cancer. For this reason, the number of people exposed to anticancer drugs has increased too. Taking this increase into consideration, in a way to make more emphasis on the new drugs, we evaluated the cardiac side effects of anticancer drugs, how these side effects should be determined and how the treatment of these side effects should be. Key words: Anticancer Drugs; Cardiotoxicity; Risk Factors; Kinase Inhibitors.

Keywords

Anticancer Drugs; Cardiotoxicity; Risk Factors; Kinase Inhibitors.

References

  • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783- 92.
  • Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
  • Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-9.
  • Rini BI: Quantifying hypertensionin patients with cancer treatd with sorafenid. Lancet Oncol 2008; 9: 86-7.
  • Khakoo AY, Yeh ET. Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5: 655-67.
  • Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2010, doi: 10.1016/j.ctrv 2010: 11.01.
  • Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, Di Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chemistry 2001; 8: 1649- 60.
  • Outomuro D, Grana DR, Azzato F, Milei J. Adriamycine- induced myocardial toxicity: New solutions for an old problem? Int J Cardiol 2007; 117: 6-15.
  • Krause DS, Van Etten RA: Tyrosine kinase as targets for cancer therapy. N Engl J Med 2005; 353: 167-72.
  • Maitland ML:Cardiovascular toxicol of new agents. Clin Adv Hematol Oncol 2008; 6: 657-9.
  • Sica DA: Angiogenesis inhibitors and hypertension:an emerging issue. J Clin Oncol 2006; 24: 1329-31.
  • Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab- induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-03.
  • Suter TM, procter M, van Veldhuisen DJ, et al. Trastuzumab- associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
  • Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.
  • Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006; 29: 567-86.
  • Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685-96.
  • Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
  • Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191-202.
  • Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-91.
  • Çeliker A. Meme kanserli hastalarda adjuvan kemoterapiye bağlı sol ventrikül disfonksiyonunun Troponin T ile erken dönemde tahmin edilmesi. 20. Ulusal Kardiyoloji Kong. Sözlü Bildiri. 2004.
  • Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19: 352-9.
  • Herman EH, Lipshultz SE, Rifai N, et al. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. Circulation 1996; 94: 1-85
  • Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162: 690-6.
  • Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97: 1991-8.
  • Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ. Dobutamine stress chocardiography:a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin- treated longterm survivors of childhood cancer. J Am Coll Cardiol 1992; 19: 394-01.
  • Jurcut R, Ganame J, D’hooge J. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer (2008) 16:437-45.
  • Neilan TG, Jassal DS, Perez-SanzTM, Raher MJ, Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006; 27: 1868-75
  • Tassan-Mangina S, Codorean D, Metivier M, Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7(2): 141-6.
  • Ganame J, Claus P, Eyskens B, Uyttebroeck A, Renard M, Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007; 99: 974-7.
  • Ganame J, Claus P, Uyttebroeck A, Renard M, D’hooge J, Myocardial dysfunction late after low dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007; 12: 1351-8.
  • Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 2006; 48: 313-20.
  • Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-79.
  • Kondo C, Fukushima K, Kusakabe K. Measurement of left ventricular volumes and ejection fraction by quantitative gated SPET, contrast ventriculography and magnetic resonance imaging: a meta-analysis. Eur J Nucl Med Mol Imaging 2003; 30: 851-8.
  • Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7: 114-21
  • Audrey H Wu.. Cardiotoxic drugs: clinical monitoring and decision making The Heart 2008; 94: 1503-9.

Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?

Year 2011, Volume: 18 Issue: 2, 137 - 142, 01.04.2011

Erdal Aktürk Ertuğrul Kurtoğlu Hakan Harputluoğlu

Abstract

Kanser tedavisinde yeni antikanser ilaçlarının kullanılması, erken tanı ve tedavi koşullarının değişmesi ile şifa oranı belirgin olarak artmıştır. Dolayısıyla kanser ilaçlarına maruz kalan kişi sayısı da artmıştır. Bu artış dikkate alınarak, yeni ilaçlara biraz daha vurgu yapacak şekilde antikanser ilaçların kardiyak yan etkilerini, bu yan etkilerin nasıl belirlenmesi gerektiğini, bunların tedavisinin ve takibinin nasıl olması gerektiğini değerlendirdik. Anahtar kelimeler: Antikanser İlaçlar; Kardiyotoksisite; Risk Faktörleri; Kinaz İnhibitörleri.

Keywords

Antikanser İlaçlar; Kardiyotoksisite; Risk Faktörleri; Kinaz İnhibitörleri.

References

  • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783- 92.
  • Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
  • Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-9.
  • Rini BI: Quantifying hypertensionin patients with cancer treatd with sorafenid. Lancet Oncol 2008; 9: 86-7.
  • Khakoo AY, Yeh ET. Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5: 655-67.
  • Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2010, doi: 10.1016/j.ctrv 2010: 11.01.
  • Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, Di Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chemistry 2001; 8: 1649- 60.
  • Outomuro D, Grana DR, Azzato F, Milei J. Adriamycine- induced myocardial toxicity: New solutions for an old problem? Int J Cardiol 2007; 117: 6-15.
  • Krause DS, Van Etten RA: Tyrosine kinase as targets for cancer therapy. N Engl J Med 2005; 353: 167-72.
  • Maitland ML:Cardiovascular toxicol of new agents. Clin Adv Hematol Oncol 2008; 6: 657-9.
  • Sica DA: Angiogenesis inhibitors and hypertension:an emerging issue. J Clin Oncol 2006; 24: 1329-31.
  • Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab- induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-03.
  • Suter TM, procter M, van Veldhuisen DJ, et al. Trastuzumab- associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
  • Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.
  • Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006; 29: 567-86.
  • Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685-96.
  • Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
  • Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191-202.
  • Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-91.
  • Çeliker A. Meme kanserli hastalarda adjuvan kemoterapiye bağlı sol ventrikül disfonksiyonunun Troponin T ile erken dönemde tahmin edilmesi. 20. Ulusal Kardiyoloji Kong. Sözlü Bildiri. 2004.
  • Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19: 352-9.
  • Herman EH, Lipshultz SE, Rifai N, et al. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. Circulation 1996; 94: 1-85
  • Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162: 690-6.
  • Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97: 1991-8.
  • Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ. Dobutamine stress chocardiography:a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin- treated longterm survivors of childhood cancer. J Am Coll Cardiol 1992; 19: 394-01.
  • Jurcut R, Ganame J, D’hooge J. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer (2008) 16:437-45.
  • Neilan TG, Jassal DS, Perez-SanzTM, Raher MJ, Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006; 27: 1868-75
  • Tassan-Mangina S, Codorean D, Metivier M, Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7(2): 141-6.
  • Ganame J, Claus P, Eyskens B, Uyttebroeck A, Renard M, Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007; 99: 974-7.
  • Ganame J, Claus P, Uyttebroeck A, Renard M, D’hooge J, Myocardial dysfunction late after low dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007; 12: 1351-8.
  • Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 2006; 48: 313-20.
  • Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-79.
  • Kondo C, Fukushima K, Kusakabe K. Measurement of left ventricular volumes and ejection fraction by quantitative gated SPET, contrast ventriculography and magnetic resonance imaging: a meta-analysis. Eur J Nucl Med Mol Imaging 2003; 30: 851-8.
  • Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7: 114-21
  • Audrey H Wu.. Cardiotoxic drugs: clinical monitoring and decision making The Heart 2008; 94: 1503-9.
There are 35 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Erdal Aktürk This is me

Ertuğrul Kurtoğlu This is me

Hakan Harputluoğlu This is me

Publication Date April 1, 2011
Published in Issue Year 2011 Volume: 18 Issue: 2

Cite

APA Aktürk, E., Kurtoğlu, E., & Harputluoğlu, H. (2011). Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?. Journal of Turgut Ozal Medical Center, 18(2), 137-142.
AMA Aktürk E, Kurtoğlu E, Harputluoğlu H. Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?. J Turgut Ozal Med Cent. April 2011;18(2):137-142.
Chicago Aktürk, Erdal, Ertuğrul Kurtoğlu, and Hakan Harputluoğlu. “Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi Ve Takip Nasıl Yapılmalı?”. Journal of Turgut Ozal Medical Center 18, no. 2 (April 2011): 137-42.
EndNote Aktürk E, Kurtoğlu E, Harputluoğlu H (April 1, 2011) Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?. Journal of Turgut Ozal Medical Center 18 2 137–142.
IEEE E. Aktürk, E. Kurtoğlu, and H. Harputluoğlu, “Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?”, J Turgut Ozal Med Cent, vol. 18, no. 2, pp. 137–142, 2011.
ISNAD Aktürk, Erdal et al. “Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi Ve Takip Nasıl Yapılmalı?”. Journal of Turgut Ozal Medical Center 18/2 (April 2011), 137-142.
JAMA Aktürk E, Kurtoğlu E, Harputluoğlu H. Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?. J Turgut Ozal Med Cent. 2011;18:137–142.
MLA Aktürk, Erdal et al. “Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi Ve Takip Nasıl Yapılmalı?”. Journal of Turgut Ozal Medical Center, vol. 18, no. 2, 2011, pp. 137-42.
Vancouver Aktürk E, Kurtoğlu E, Harputluoğlu H. Kanser ilaçlarının Kardiyovasküler Yan Etkileri: Bu Yan Etkiler Nasıl Belirlenmeli, Tedavi ve Takip Nasıl Yapılmalı?. J Turgut Ozal Med Cent. 2011;18(2):137-42.